B. N. Hangalapura, D. Oosterhoff, T. Gupta, J. de Groot, P. G. Wijnands, V. W. van Beusechem, J. den Haan, T. Tuting, A. J. van den Eertwegh, D. T. Curiel, R. J. Scheper and T. D. de Gruijl, “Delivery Route, MyD88 Signaling and Cross-Priming Events Determine the Anti-Tumor Efficacy of an Adenovirus Based Melanoma Vaccine,” Vaccine, Vol. 29, No. 12, 2011, pp. 2313-2321. doi:10.1016/j.vaccine.2011.01.022

has been cited by the following article:

• TITLE: Melanoma Immunotherapy: Overcoming Obstacles to Augment Anti-Tumor Immune Responses

  AUTHORS: Kristian M. Hargadon

  KEYWORDS: Melanoma; Tumor Immunotherapy; Dendritic Cell; Tumor Antigen; T Cell; Vaccine; Adoptive Transfer

  JOURNAL NAME: Journal of Cosmetics, Dermatological Sciences and Applications, Vol.3 No.2A, June 20, 2013

  ABSTRACT: Melanoma is the most aggressive form of skin cancer and accounts for the vast majority of skin cancer-related deaths. Its ability to metastasize quickly, often before diagnosis, makes this cancer difficult to treat with traditional therapies. The identification of anti-melanoma immune responses in patients and the discovery of tumor antigens targeted by these immune responses have paved the way for immunotherapy as a novel approach to treating this cancer. In this review, the major immunotherapies targeting these melanoma tumor antigens are discussed. The advantages and limitations of peptide-, protein-, and gene-based vaccination maneuvers and adoptive cell transfer therapies are emphasized. Recent insights into melanoma immune evasion strategies are also highlighted, with particular focus on how our increasing knowledge of tumor/immune cell interactions is driving the development of novel immunotherapeutic strategies for the treatment of melanoma.